182 related articles for article (PubMed ID: 37224883)
21. Course of platelet miRNAs after cessation of P2Y12 antagonists.
Jäger B; Stojkovic S; Haller PM; Piackova E; Kahl BS; Andric T; Vargas KG; Wojta J; Huber K
Eur J Clin Invest; 2019 Aug; 49(8):e13149. PubMed ID: 31172515
[TBL] [Abstract][Full Text] [Related]
22. Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.
Traby L; Kollars M; Kaider A; Eichinger S; Wolzt M; Kyrle PA
J Thromb Haemost; 2016 Feb; 14(2):273-81. PubMed ID: 26663880
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
24. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Gager GM; Jilma B; Winter MP; Hengstenberg C; Lang IM; Toma A; Prüller F; Wallner M; Kolesnik E; von Lewinski D; Siller-Matula JM
Eur J Clin Invest; 2020 Nov; 50(11):e13304. PubMed ID: 32506444
[TBL] [Abstract][Full Text] [Related]
25. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Deharo P; Quilici J; Camoin-Jau L; Johnson TW; Bassez C; Bonnet G; Fernandez M; Ibrahim M; Suchon P; Verdier V; Fourcade L; Morange PE; Bonnet JL; Alessi MC; Cuisset T
JACC Cardiovasc Interv; 2017 Dec; 10(24):2560-2570. PubMed ID: 29268886
[TBL] [Abstract][Full Text] [Related]
26. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
[TBL] [Abstract][Full Text] [Related]
27. Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y
Chyrchel B; Drożdż A; Długosz D; Stępień EŁ; Surdacki A
Int J Med Sci; 2019; 16(2):264-275. PubMed ID: 30745807
[No Abstract] [Full Text] [Related]
28. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.
Guimarães PO; Franken M; Tavares CAM; Silveira FS; Antunes MO; Bergo RR; Joaquim RM; Hirai JCS; Andrade PB; Pitta FG; Mariani J; Nascimento BR; de Paula JET; Silveira MS; Costa TAO; Dall'Orto FTC; Serpa RG; Sampaio FBA; Ohe LN; Mangione FM; Furtado RHM; Sarmento-Leite R; Monfardini F; Assis SRL; Nicolau JC; Sposito AC; Lopes RD; Onuma Y; Valgimigli M; Angiolillo DJ; Serruys PW; Berwanger O; Bacal F; Lemos PA
EuroIntervention; 2023 Jul; 19(4):e323-e329. PubMed ID: 37306039
[TBL] [Abstract][Full Text] [Related]
29. Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis.
Selhorst G; Schmidtler F; Ott A; Hitzke E; Tomelden J; Antoni D; Hoffmann E; Rieber J
Platelets; 2019; 30(3):341-347. PubMed ID: 29521570
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study.
Soueid AE; Kassas I; Rade J; Kakouros N
J Invasive Cardiol; 2021 Apr; 33(4):E263-E268. PubMed ID: 33794478
[TBL] [Abstract][Full Text] [Related]
31. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
[TBL] [Abstract][Full Text] [Related]
32. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
[TBL] [Abstract][Full Text] [Related]
33. Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor.
Angiolillo DJ; Been L; Rubinstein M; Martin M; Rollini F; Franchi F
J Thromb Thrombolysis; 2021 Apr; 51(3):741-747. PubMed ID: 33582955
[TBL] [Abstract][Full Text] [Related]
34. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
[TBL] [Abstract][Full Text] [Related]
35. Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy.
Hennigan BW; Good R; Adamson C; Parker WAE; Martin L; Anderson L; Campbell M; Serruys PW; Storey RF; Oldroyd KG
Platelets; 2022 Jan; 33(1):141-146. PubMed ID: 33356730
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
[TBL] [Abstract][Full Text] [Related]
37. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
[TBL] [Abstract][Full Text] [Related]
38. Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention.
Kim Y; Jeong MH; An M; Cho K; Hong Y; Kim J; Ahn Y
PLoS One; 2023; 18(2):e0278993. PubMed ID: 36821598
[TBL] [Abstract][Full Text] [Related]
39. P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Povsic TJ; Ohman EM; Roe MT; White J; Rockhold FW; Montalescot G; Cornel JH; Nicolau JC; Steg PG; James S; Bode C; Welsh RC; Plotnikov AN; Mundl H; Gibson CM
JAMA Cardiol; 2019 Jul; 4(7):680-684. PubMed ID: 31141104
[TBL] [Abstract][Full Text] [Related]
40. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Abergel E; Nikolsky E
Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
